Blog Profile / Pharmalot

Filed Under:Medical / Pharmaceutical
Posts on Regator:3513
Posts / Week:10.3
Archived Since:November 10, 2008

Blog Post Archive

Actavis Must Keep its Older Alzheimer’s Pill on the Market

A federal appeals court ruled that Actavis cannot pull an older Alzheimer’s drug from the market in order to switch patients to a newer, more expensive version before generic competition emerged.

EMA Upholds Recommendation to Suspend Drugs Over ‘Flawed’ Studies

The European Medicines Agency is sticking with a decision to recommend suspending the sale of hundreds of drugs that were authorized for use based on what it called “flawed” studies that were conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India.

Pharmalot.. Pharmalittle.. As the Weekend Nears: We’re Catching up on Amgen, Merck and Lots More!!

And so, another working week is about to draw to a close. Although we sense things are already slowing down since we have a long holiday weekend coming up on this side of the pond. In any event, this is our treasured signal to daydream about weekend plans and our agenda is rather modest. Show More Summary

From Pharma to Farmer: FDA Wants Sales Data on Antibiotics for Livestock

The FDA has proposed a rule that would require drug makers to report the amount of antibiotics that are sold for use in different types of food-producing livestock.

Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru

The heated battle between drug makers and patient advocates over patents and access to medicines is moving to Peru, where several consumer groups are urging the government to issue a compulsory license for an HIV medicine sold by Bristol-Myers Squibb.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on CVS, Antibiotics and More!!

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say 'Every brand new day should...Show More Summary

Will the J&J Deal With Achillion Transform the Hep C Market?

Wall Street analysts say the Johnson & Johnson deal with Achillion Pharmaceuticals could eventually chip away at Gilead Sciences revenue and poses a threat to AbbVie.

Hospitals Urge Congress not to Change a Drug Discount Program

Executives from more than 500 hospitals are urging Congressional leaders not to make changes to a prescription drug program that serves indigent patients and bolsters their own bottom lines.

High Price for Gilead Sciences Hep C Drug Prompts Patent Challenges

Several advocacy groups have filed patent challenges to the blockbuster Sovaldi hepatitis c drug in a bid to widen access to patients in some of the world’s largest countries.

Pharmalot.. Pharmalitlle.. Good Morning: We’re Catching up on J&J, Sarepta and Lots More!!

Hello, everyone, and nice to see you again. We were away the past few days on what amounted to a long holiday weekend with one of our short people. Besides taking a needed break, creating memories can be important, yes? Now, though, we have returned to the usual routine of deadlines, meetings and the rest. Show More Summary

Pharmalot… Pharmalittle… Good Morning: We’re Catching Up on Endo, J&J, Merck and More . . .

Good morning. Ed Silverman is away from the Pharm one more day and we can only wonder what he’s brewing this morning. We're pouring French roast at the alternate campus where it is rainy and foggy, but where a bluebird on the feeder has already brightened the day. Show More Summary

Pharmalot… Pharmalittle… Good Morning: We’re Reading About Endo, Eleven Biotherapeutics and More!!

Endo International PLC is buying Par Pharmaceutical Holdings from a private equity firm for about $8 billion in cash and stock.

Pharmalot… Pharmalittle… We’re Reading About Actavis, Circassia and More!!

Drug maker Actavis PLC has booked a “contingent liability” and held discussions with the Justice Department about resolving an investigation into the marketing tactics its Warner Chilcott division, including allegations of improper payments to doctors, according to a regulatory filing and court documents.

FDA and Mallinckrodt Lock Horns Over the Right to Sell Generic Concerta

An unusual lawsuit claims the FDA overstepped its bounds by deciding two generic drugs used to treat ADHD should no longer be substituted for the widely used Concerta treatment, and the outcome has broad implications for generic drug makers and the agency.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Pfizer, Antibiotics and Lots More!!

Rise and shine, everyone, another busy day is on the way. This morning is getting off to a fabulous start, though, as a delightfully warm sun is enveloping the subdued Pharmalot campus, where the officials mascots are snoozing and the short people are gainfully occupied. Show More Summary

Orexigen and Takeda Feud Over Cost of a Controversial Diet Drug Trial

Amid accusations the drug maker misled investors and patients about the safety of its drug, Orexigen Therapeutics is now feuding with Takeda Pharmaceutical, its marketing partner, over the cost of a clinical trial that was required by the FDA.

Prescription Drug Costs Rose Faster Than Ever for Many Americans: Report

The prices for new hepatitis C and cancer treatments are driving the cost of prescription drugs to new highs for more Americans, according to a new report.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Vertex, AstraZeneca and More!!

Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made is this far, which is a likely sign of surviving another few days. Show More Summary

Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs

U.S. Sen. Bernie Sanders (I-VT.) has asked the U.S. Department of Veterans Affairs to use emergency powers to break the patents on high-priced hepatitis C medicines sold by several drug makers, including Gilead Sciences.

Copyright © 2015 Regator, LLC